Ordinary Index Rebalancing in the Solactive Pharma Breakthrough Value Index | March 2021

In the ordinary rebalance the following composition will be implemented effective open 22.03.2021:

ABBVIE INC
ALEXION PHARMACEUTICALS INC
BASILEA PHARMACEUTICA LTD.
BEIGENE LTD-ADR
BIOGEN INC
BIOMARIN PHARMACEUTICAL INC
BRISTOL-MYERS SQUIBB CO
CHUGAI PHARMACEUTICAL CO LTD ORD
CSL LTD ORD
EISAI
EMERGENT BIOSOLUTIONS INC
ENDO INTERNATIONAL PLC
GENMAB A/S
GRIFOLS SA CLASS A
H LUNDBECK AS
HALOZYME THERAPEUTICS INC
HORIZON THERAPEUTICS PLC
INCYTE CORP
IPSEN SA
JAZZ PHARMACEUTICALS PLC
JOHNSON & JOHNSON
KYOWA KIRIN CO LTD
LIGAND PHARMACEUTICALS INC
NEKTAR THERAPEUTICS
NIPPON SHINYAKU CO LTD
NOVARTIS AG
ROCHE HOLDING AG
SANOFI SA
SUPERNUS PHARMACEUTICALS INC
SWEDISH ORPHAN BIOVITRUM AB
TAKEDA PHARMACEUTICAL
TRAVERE THERAPEUTICS INC
ULTRAGENYX PHARMACEUTICAL INC
UNITED THERAPEUTICS CORP
VERTEX PHARMACEUTICALS INC